"The U.S. Food and Drug Administration today granted approval to Lenvima (lenvatinib) to treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine"...
Valtropin® 5 mg
(somatropin rDNA origin for injection, USP)
Valtropin (somatropin injection) ® [somatropin (rDNA origin) for injection] is a polypeptide hormone of recombinant DNA origin. The hormone is produced by recombinant DNA technology in yeast cells (Saccharomyces cerevisiae). Valtropin (somatropin injection) ® has 191 amino acid residues and a molecular weight of 22,125 daltons. The amino acid sequence of the product is identical to that of human growth hormone (hGH) of pituitary origin.
Valtropin (somatropin injection) ® is a sterile, non-pyrogenic, white to almost white, lyophilized powder intended for subcutaneous injection after reconstitution. Each vial contains 5 mg somatropin (approximately 15 International Units), 10 mg glycine, 45 mg mannitol, 0.22 mg monobasic sodium phosphate, and 2.98 mg dibasic sodium phosphate. The pH is adjusted with sodium hydroxide and/or hydrochloric acid. A pre-filled syringe of 1.5 mL clear solution diluent is provided for reconstitution of the powder. The pre-filled syringe contains 1.5 mL Water for Injection and 0.3% w/v metacresol as an antimicrobial preservative. After reconstitution with 1.5 mL diluent, the solution contains 3.33 mg/mL of somatropin.
Last reviewed on RxList: 4/30/2007
This monograph has been modified to include the generic and brand name in many instances.
Additional Valtropin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.